

9 from the group consisting of an hypoxic site, an ischemic site, a stress site, and a site being a combination of at least two of an hypoxic site, an ischemic site, and a stress site.

9 90. (Amended) The mononuclear phagocyte according to claim 89 wherein the binding agent comprises a mannosylated poly - L -lysine ligand.

9 101. (Amended) The mononuclear phagocyte according to claim 87 wherein the mononuclear phagocyte further comprises an NOI encoding HIF1-alpha or a tetracycline repressor protein.

9 109. (Amended) A delivery system for targeting a mononuclear phagocyte according to claim 87 to a target sitesselected from the group consisting of an hypoxic site, an ischemic site, a stress site, and a site being a combination of at least two of an hypoxic site, an ischemic site, and a stress site.

110. (Amended) The mononuclear phagocyte according to claim 87 wherein the hypoxia, ischemic or stress is a tumour associated condition.

9 121. (Amended) A pharmaceutical composition comprising a construct according to claim 111 optionally admixed with a pharmaceutically acceptable diluent, excipient or